USE IR-Spectroscopy in treatment oncology patient with bone metastases by 153 Smoxabifor

Abstract

Using infrared spectroscopy, we studied the character of intermolecular interactions in the samples blood plasma of oncological patients with bone metastases in the treatment of their modern β-emitter 153Sm-oxabifor. The therapeutic dose of the 153Sm-oxabifor was 1.0 mCi/kg of the patient's body weight. Analysis of the IR-spectra showed that already after the rst course of palliative radionuclide therapy there is a tendency to balance the products of free radical nature and antioxidants, which indicates the e ectiveness of the treatment. Molecular changes in the blood plasma of cancer patients with bone metastases registered using infrared spectroscopy are speci c during palliative therapy.